University of Limerick Institutional Repository

Neonatal screening programme for CF: Results from the Irish Comparative Outcomes Study (ICOS)

DSpace Repository

Show simple item record

dc.contributor.author Fitzgerald, Catherine
dc.contributor.author Linnane, Barry
dc.contributor.author George, Sherly
dc.contributor.author Ni Chronin, Muireann
dc.contributor.author Mullane, David
dc.contributor.author Herzig, Mary
dc.contributor.author Greally, Peter
dc.contributor.author Elnazir, Basil
dc.contributor.author Healy, Fiona
dc.contributor.author McNally, Paul
dc.contributor.author Javadpour, Sheila
dc.contributor.author Cox, Des
dc.contributor.author Fitzpatrick, Patricia
dc.date.accessioned 2020-07-24T14:31:05Z
dc.date.issued 2020
dc.identifier.uri http://hdl.handle.net/10344/9041
dc.description peer-reviewed en_US
dc.description The full text of this article will not be available in ULIR until the embargo expires on the 29/05/2021
dc.description.abstract The introduction of NBS in Ireland in July 2011, provided a unique opportunity to investigate clinical outcomes using a comparative historical cohort study. Clinical cohort: children clinically diagnosed with CF born 1 July 2008 to 30 June 2011, and NBS cohort: children diagnosed with CF through NBS born 1 July 2011 to 30 June 2016. Clinical data were collected from the CF Registry of Ireland, medical charts, and data on weight/height before diagnosis from public health nurses and family doctors. SPSS was used for analysis. A total of 232 patients were recruited (response 93%) (93 clinically diagnosed, 139 NBS‐detected). Following exclusions of meconium ileus (MI) (40), diagnosis outside Ireland (4), and being designated as CFSPID (2), a total of 77 clinically diagnosed patients and 109 NBS detected children were included in analysis. Over half were homozygous for F508del mutation. Being clinically diagnosed was independently associated with hospitalization for infective exacerbation of CF < 36 months (OR, 2.80; 95%CI 1.24‐6.29). Diagnosis to first acquisition of Pseudomonas aeruginosa was significantly longer in NBS than clinically detected; from birth there was no significant difference. Weight and length/height were significantly greater in NBS cohort at 6 and 12 months. We provide evidence of improved growth, reduced hospitalization for acute exacerbations, and delayed P. aeruginosa acquisition (from diagnosis) to age 3 for the NBS cohort. Screening practices likely account for the non‐significant difference in P. aeruginosa acquisition from birth. en_US
dc.language.iso eng en_US
dc.publisher Wiley and Sons Ltd en_US
dc.relation.ispartofseries Pediatric Pulmonology;
dc.relation.uri https://doi.org/10.1002/ppul.24876
dc.rights This is the peer reviewed author version of the following article:Neonatal screening programme for CF: Results from the Irish Comparative Outcomes Study (ICOS) , which has been published in final form at https://doi.org/10.1002/ppul.24876. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. http://olabout.wiley.com/WileyCDA/Section/id-828039.html#terms en_US
dc.subject cystic fibrosis en_US
dc.subject screening en_US
dc.subject cohort en_US
dc.subject ICOS en_US
dc.title Neonatal screening programme for CF: Results from the Irish Comparative Outcomes Study (ICOS) en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.1002/ppul.24876
dc.date.embargoEndDate 2021-05-29
dc.embargo.terms 2021-05-29 en_US
dc.rights.accessrights info:eu-repo/semantics/embargoedAccess en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics